(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193816 A1

(51) International Patent Classification:
A61K 31/662 (2006.01) *A61P 1/16* (2006.01)
A61K 9/20 (2006.01) *A61P 13/12* (2006.01)
A61K 38/26 (2006.01) *A61P 43/00* (2006.01)
A61K 47/64 (2017.01)

(21) International Application Number:
PCT/US2025/019549

(22) International Filing Date:
12 March 2025 (12.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/565,442 14 March 2024 (14.03.2024) US

(71) Applicant: **VIKING THERAPEUTICS, INC.** [US/US]; 9920 Pacific Heights Blvd., Suite 350, San Diego, CA 92121 (US).

(72) Inventors: **LIAN, Brian**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, CA 92121 (US). **BARKER, Geoffrey, E.**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, CA 92121 (US). **BARNES, Maureen**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, CA 92121 (US). **GONZALEZ, Jake**; c/o Viking Therapeutics, Inc., 9920 Pacific Heights Blvd., Suite 350, San Diego, CA 92121 (US).

(74) Agent: **LOZAN, Vladimir**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS

(57) Abstract: Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP/GLP-1 dual receptor agonists and uses thereof.

WO 2025/193816 A1